Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug;27(8):1186-1196.
doi: 10.1038/s41431-019-0390-9. Epub 2019 Apr 8.

Evaluation of telephone genetic counselling to facilitate germline BRCA1/2 testing in women with high-grade serous ovarian cancer

Affiliations

Evaluation of telephone genetic counselling to facilitate germline BRCA1/2 testing in women with high-grade serous ovarian cancer

Erin Tutty et al. Eur J Hum Genet. 2019 Aug.

Abstract

Systemic healthcare issues and geographical challenges restrict women's access to BRCA1/2 testing to inform the use of tailored treatments for high-grade serous ovarian cancer. Consequently, BRCA1/2 testing in this population is low and improved testing pathways are urgently needed. This study aimed to determine the acceptability and feasibility of telephone genetic counselling (TGC) to facilitate treatment-focused BRCA1/2 testing in Australia for women with high-grade serous ovarian cancer. Women who received TGC were invited to complete a survey examining their experiences of the service. A cost analysis was conducted to compare the service to standard, in-person genetic counselling. One hundred and seven women responded (48% response rate); 8 had a BRCA1/2 variant affecting function. Geographical barriers prevented women from accessing genetic services in the past. All participants had a positive attitude towards testing, and regret following testing was minimal. While the impact of testing was greater for those with a positive test result, overall, genetic testing did not put the additional psychosocial burden on the participants. Participant's evaluations of the telephone interactions with the genetic counsellors were highly satisfactory. The service was also found to be cost-effective. This model of telephone genetic counselling was an acceptable and effective way to reduce barriers to BRCA1/2 testing for women with ovarian cancer.

PubMed Disclaimer

Conflict of interest statement

Bettina Meiser has a remunerated consultant role with the company Astrazeneca with respect to an unrelated project. The remaining authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Flowchart of women participating in the study. No variant detected = Neg, BRCA1/2 variant affecting function = Pos, Variant of uncertain significance = VUS. 1Telephone disconnected, email undeliverable and/or survey package returned to sender. 2n = 9 had a child participate in TGC on their behalf and n = 4 required an interpreter. 3Upon follow up via telephone, n = 11 expressed an interest in the study but had yet to respond, including n = 2 positive women who explained they were too busy at the time. 4n = 3 stated that they could not remember their result, but were confirmed to have a negative result in the database. 5n = 10 were inpatients at the time of follow up (including n = 1 pos), n = 8 believed they had not received telephone genetic counselling
Fig. 2
Fig. 2
Preferred health professional to facilitate BRCA1/2 testing. * Genetic counsellor ** General practitioner. a8 women had no preference, 6 women were unsure how to answer this question and 3 missing responses. b14 women had no preference, 3 women were unsure how to answer this question and 3 missing responses

References

    1. George A, Kaye S, Banerjee S. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. Nat Rev Clin Oncol. 2017;14:284. doi: 10.1038/nrclinonc.2016.191. - DOI - PubMed
    1. Alsop K, Fereday S, Meldrum C. BRCA mutation frequency and patterns of treatment response in BRCA mutation–positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J of Clin Onc. 2012;30:2654. doi: 10.1200/JCO.2011.39.8545. - DOI - PMC - PubMed
    1. Plaskocinska I, Shipman H, Drummond J, Thompson E, Buchanan V, Newcombe B, et al. New paradigms for BRCA1/BRCA2 testing in women with ovarian cancer: results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study. J Med Genet. 2016;53:655–61. doi: 10.1136/jmedgenet-2016-103902. - DOI - PMC - PubMed
    1. Meiser B, Gleeson M, Kasparian N, Barlow-Stewart K, Ryan M, Watts K, et al. There is no decision to make: experiences and attitudes toward treatment-focused genetic testing among women diagnosed with ovarian cancer. Gynecol Oncol. 2012;124:153–7. doi: 10.1016/j.ygyno.2011.09.040. - DOI - PubMed
    1. George A, Riddell D, Seal S, Talukdar S, Mahamdallie S, Ruark E, et al. Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients. Sci Rep. 2016;6:29506. doi: 10.1038/srep29506. - DOI - PMC - PubMed

Publication types

MeSH terms